We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Collegium Pharmaceutical (COLL - Free Report) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 12.9%. It is anticipated that revenues will amount to $147.04 million, exhibiting an increase of 1.6% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Collegium Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Total product revenues- Belbuca' of $50.44 million. The estimate points to a change of +14.1% from the year-ago quarter.
The consensus among analysts is that 'Total product revenues- Nucynta' will reach $44.46 million. The estimate indicates a change of -9.3% from the prior-year quarter.
Analysts expect 'Total product revenues- Symproic' to come in at $4.04 million. The estimate indicates a year-over-year change of +10.6%.
Analysts predict that the 'Total product revenues- Xtampza ER' will reach $49.05 million. The estimate suggests a change of +2.5% year over year.
Over the past month, Collegium Pharmaceutical shares have recorded returns of -6.1% versus the Zacks S&P 500 composite's -0.4% change. Based on its Zacks Rank #3 (Hold), COLL will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Collegium Pharmaceutical (COLL - Free Report) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 12.9%. It is anticipated that revenues will amount to $147.04 million, exhibiting an increase of 1.6% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Collegium Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Total product revenues- Belbuca' of $50.44 million. The estimate points to a change of +14.1% from the year-ago quarter.
The consensus among analysts is that 'Total product revenues- Nucynta' will reach $44.46 million. The estimate indicates a change of -9.3% from the prior-year quarter.
Analysts expect 'Total product revenues- Symproic' to come in at $4.04 million. The estimate indicates a year-over-year change of +10.6%.
Analysts predict that the 'Total product revenues- Xtampza ER' will reach $49.05 million. The estimate suggests a change of +2.5% year over year.
View all Key Company Metrics for Collegium Pharmaceutical here>>>
Over the past month, Collegium Pharmaceutical shares have recorded returns of -6.1% versus the Zacks S&P 500 composite's -0.4% change. Based on its Zacks Rank #3 (Hold), COLL will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>